Compound News and Research

RSS

Naringenin from grape fruits initiates increased fatty acid oxidation, inhibits vLDL production

Naringenin, an antioxidant derived from the bitter flavor of grapefruits and other citrus fruits, may cause the liver to break down fat while increasing insulin sensitivity, a process that naturally occurs during long periods of fasting.

26 Aug 2010

Study on current insect repellants confirms need for better insect repellants

Fire up the citronella-scented tiki torches, and slather on the DEET: Everybody knows these simple precautions repel insects, notably mosquitoes, whose bites not only itch and irritate, but also transmit diseases such as West Nile virus, malaria and dengue. Now, Johns Hopkins scientists have discovered what it is in the bugs' molecular makeup that enables citronellal (the aromatic liquid used in lotions, sprays and candles) and DEET, to deter insects from landing and feeding on you. A better understanding of these molecular-behavioral links already is aiding the team's search for more effective repellants.

26 Aug 2010

Continuous boosting of natural painkiller shuts down brain cell receptor response

ERepeatedly boosting brain levels of one natural painkiller soon shuts down the brain cell receptors that respond to it, so that the painkilling effect is lost, according to a surprising new study led by Scripps Research Institute and Virginia Commonwealth University scientists. The study has important implications for drug development.

25 Aug 2010

Eisai's Phase III trial of Perampanel for epilepsy shows positive results

The double-blind, placebo-controlled, parallel-group study (Study 306) showed that perampanel was well-tolerated and effective in reducing median seizure frequency and increasing responder rates, the primary outcome measures in the United States and European Union, respectively. The findings were highly statistically significant in 4 mg and 8 mg doses compared to placebo.

25 Aug 2010

First patient treated in Synta Pharmaceuticals' clinical trial of STA-9090

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the first patient has been treated in its clinical trial of STA-9090 in combination with docetaxel for the treatment of advanced solid tumor malignancies.

24 Aug 2010

CAHG adopts new integrated marketing communications network model

Corbett Accel Healthcare Group is now CAHG, having adopted a new integrated marketing communications network model designed to deliver MarketMovingIdeas® in support of their clients' brands. Complementing the new agency network brand is a new vision, We Grow Leaders, which reflects the agency network's devotion to the development of leadership brands, ideas and talent.

24 Aug 2010

Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease

Genzyme Corporation announced today that the two-year follow-up results from the phase 2 clinical trial of its investigational therapy known as eliglustat tartrate have been accepted for publication in the journal Blood. The results have been pre-published on the journal's website and are available to subscribers.

23 Aug 2010

Researchers find medication for diabetes, smoking cessation

The script for two research teams inducted today into the American Chemical Society (ACS) scientific "hall of fame" the ACS Heroes of Chemistry is a tale of two pills. One team invented a medication that helps people with diabetes control their blood sugar levels. The second team invented a medicine that helps people stop smoking, an addiction that experts regard as today's single greatest preventable cause of death worldwide.

23 Aug 2010

New antisense drugs may help treat accidental infections: Study

New studies show that treatments targeting specific viral genes protected monkeys infected with deadly Ebola or Marburg viruses. Furthermore, the animals were protected even when therapeutics were administered one hour after exposure-suggesting the approach holds promise for treating accidental infections in laboratory or hospital settings.

23 Aug 2010

Scientists identify compound to treat Chagas' disease

A new compound may offer an effective drug candidate against the deadly tropical infection, Chagas' disease say researchers from Brazil. They report their findings in the August 2010 issue of the journal Antimicrobial Agents and Chemotherapy.

21 Aug 2010

SRI and Taiho collaborate to advance clinical development of TAS-108 breast cancer program

SRI International, an independent nonprofit research and development organization, announced today that it has assumed responsibility for further clinical development of the TAS-108 breast cancer program, in cooperation with Taiho Pharmaceuticals Co., Ltd., a leading Japanese pharmaceutical company. Further clinical development will focus on the lead compound's registration for the treatment of tamoxifen and aromatase inhibitor-resistant breast cancers.

20 Aug 2010

Research marks new direction to treat Pneumocystis, inflammatory diseases

A drug to treat inflammation plays a surprising role reducing the level of infection caused by an opportunistic bug that is deadly for AIDS and cancer patients and others with weakened immune systems.

20 Aug 2010

Cetero Research expands Clinical Dermatology and Transdermal Delivery System services

Cetero Research, the leading early stage contract research organization (CRO), today announced the expansion of multiple Clinical Dermatology and Transdermal Delivery System (TDDS) services to four Cetero clinical facilities.

20 Aug 2010

New ways to tackle diabetes

According to a new analysis from UK, a diet rich in green leafy vegetables may reduce the risk of developing diabetes. The inference was drawn from six studies which looked into fruit and vegetable intake and found that only food including spinach and cabbage was found to have a significant positive effect. The findings were published in the British Medical Journal (BMJ).

19 Aug 2010

Montana State University offers new biomedical technologies for prevention, treatment of viral infections

Researchers at Montana State University have developed six new biomedical technologies that could have applications for treating antibiotic resistant infections, fungal infections and viral infections; boosting humans' innate immunity and improving scientists' ability to study such compounds. The technologies are available for licensing to interested companies and entrepreneurs.

19 Aug 2010

FDA grants orphan drug designation to ImmunoGen's lorvotuzumab mertansine for small-cell lung cancer

ImmunoGen, Inc., a biotechnology company that develops antibody-based targeted anticancer products, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its lorvotuzumab mertansine (formerly IMGN901) product candidate when used for the treatment of small-cell lung cancer (SCLC).

19 Aug 2010

Achillion Pharmaceuticals enters agreement to raise $50.1 million from sale of common stock

Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that it has entered into definitive agreements for the purchase of $50.1 million of Achillion's common stock and warrants in a private placement financing with a select group of institutional and accredited investors, namely Domain Associates, Clarus Ventures, Quaker BioVentures and Pappas Ventures.

19 Aug 2010

Biogen Idec, Knopp Neurosciences enter license agreement for KNS-760704 ALS drug candidate

Biogen Idec and Knopp Neurosciences today announced they have entered into an exclusive, worldwide license agreement under which Biogen Idec will develop and commercialize KNS-760704 (dexpramipexole) for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, and potentially other indications.

18 Aug 2010

Xcelligence System provides real-time detection of neuronal cell death

Time course analyses of neuronal cell death and its underlying mechanisms require laborious experiments and multiple endpoint assays, often involving labelling with irritating compounds and cell disruption. A recent study used the xCELLigence System of Roche to investigate the response of the neuronal-like cell line HT-22 and cultured primary rat cortical neurons to different cell death stimuli and neuroprotectants.

18 Aug 2010

Lilly to halt development of potential Alzheimer's disease drug semagacestat

Eli Lilly and Company will halt development of semagacestat, a gamma secretase inhibitor being studied as a potential treatment for Alzheimer's disease, because preliminary results from two ongoing long-term Phase III studies showed it did not slow disease progression and was associated with worsening of clinical measures of cognition and the ability to perform activities of daily living.

18 Aug 2010

Compound News and Research

Naringenin from grape fruits initiates increased fatty acid oxidation, inhibits vLDL production

Study on current insect repellants confirms need for better insect repellants

Continuous boosting of natural painkiller shuts down brain cell receptor response

Eisai's Phase III trial of Perampanel for epilepsy shows positive results

First patient treated in Synta Pharmaceuticals' clinical trial of STA-9090

CAHG adopts new integrated marketing communications network model

Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease

Researchers find medication for diabetes, smoking cessation

New antisense drugs may help treat accidental infections: Study

Scientists identify compound to treat Chagas' disease

SRI and Taiho collaborate to advance clinical development of TAS-108 breast cancer program

Research marks new direction to treat Pneumocystis, inflammatory diseases

Cetero Research expands Clinical Dermatology and Transdermal Delivery System services

New ways to tackle diabetes

Montana State University offers new biomedical technologies for prevention, treatment of viral infections

FDA grants orphan drug designation to ImmunoGen's lorvotuzumab mertansine for small-cell lung cancer

Achillion Pharmaceuticals enters agreement to raise $50.1 million from sale of common stock

Biogen Idec, Knopp Neurosciences enter license agreement for KNS-760704 ALS drug candidate

Xcelligence System provides real-time detection of neuronal cell death

Lilly to halt development of potential Alzheimer's disease drug semagacestat

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News